WO2000055633A3 - Methodes permettant de diagnostiquer du cancer colo-rectal, compositions, et methodes permettant de detecter des modulateurs du cancer colo-rectal - Google Patents

Methodes permettant de diagnostiquer du cancer colo-rectal, compositions, et methodes permettant de detecter des modulateurs du cancer colo-rectal Download PDF

Info

Publication number
WO2000055633A3
WO2000055633A3 PCT/US2000/007044 US0007044W WO0055633A3 WO 2000055633 A3 WO2000055633 A3 WO 2000055633A3 US 0007044 W US0007044 W US 0007044W WO 0055633 A3 WO0055633 A3 WO 0055633A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
colorectal cancer
screening
cancer modulators
modulators
Prior art date
Application number
PCT/US2000/007044
Other languages
English (en)
Other versions
WO2000055633A2 (fr
WO2000055633A9 (fr
Inventor
David Mack
Kurt C Gish
Keith E Wilson
Original Assignee
Eos Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/268,866 external-priority patent/US6316272B1/en
Priority claimed from US09/436,983 external-priority patent/US6294343B1/en
Priority claimed from US09/435,945 external-priority patent/US6773878B1/en
Priority to JP2000605214A priority Critical patent/JP2004510951A/ja
Priority to AU37553/00A priority patent/AU3755300A/en
Priority to CA002369319A priority patent/CA2369319A1/fr
Priority to MXPA01009369A priority patent/MXPA01009369A/es
Priority to EP00916451A priority patent/EP1163524A2/fr
Application filed by Eos Biotechnology Inc filed Critical Eos Biotechnology Inc
Publication of WO2000055633A2 publication Critical patent/WO2000055633A2/fr
Priority to US09/733,756 priority patent/US20030198951A1/en
Publication of WO2000055633A3 publication Critical patent/WO2000055633A3/fr
Publication of WO2000055633A9 publication Critical patent/WO2000055633A9/fr
Priority to US10/254,289 priority patent/US20030118509A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des méthodes utiles pour le diagnostic et le pronostic du cancer colo-rectal. L'invention concerne également des méthodes permettant de détecter la capacité que possèdent des agents bioactifs candidats pour moduler un cancer colo-rectal. L'invention concerne en outre des méthodes et des cibles moléculaires (gènes et leurs produits) permettant d'effectuer une intervention thérapeutique pour lutter contre le cancer colo-rectal et d'autres types cancers.
PCT/US2000/007044 1999-03-15 2000-03-15 Methodes permettant de diagnostiquer du cancer colo-rectal, compositions, et methodes permettant de detecter des modulateurs du cancer colo-rectal WO2000055633A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2000605214A JP2004510951A (ja) 1999-03-15 2000-03-15 結腸直腸癌を診断する新規の方法、組成物、結腸直腸癌調節のためのスクリーニング法
AU37553/00A AU3755300A (en) 1999-03-15 2000-03-15 Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
CA002369319A CA2369319A1 (fr) 1999-03-15 2000-03-15 Methodes permettant de diagnostiquer du cancer colo-rectal, compositions, et methodes permettant de detecter des modulateurs du cancer colo-rectal
MXPA01009369A MXPA01009369A (es) 1999-03-15 2000-03-15 Nuevos metodos para el diagnostico del cancer colorectal, composiciones, y metodos para seleccionar moduladores del cancer colorectal.
EP00916451A EP1163524A2 (fr) 1999-03-15 2000-03-15 Methodes permettant de diagnostiquer du cancer colo-rectal, compositions, et methodes permettant de detecter des modulateurs du cancer colo-rectal
US09/733,756 US20030198951A1 (en) 1999-12-02 2000-12-08 Novel methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators
US10/254,289 US20030118509A1 (en) 2000-01-28 2002-09-24 Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US09/268,866 US6316272B1 (en) 1999-03-15 1999-03-15 Methods of diagnosis of colorectal cancer and methods of screening for colorectal cancer modulators
US09/268,866 1999-03-15
US09/435,945 US6773878B1 (en) 1999-11-09 1999-11-09 Methods of diagnosing of colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
US09/436,983 1999-11-09
US09/435,945 1999-11-09
US09/436,983 US6294343B1 (en) 1999-11-09 1999-11-09 Methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
US45085799A 1999-11-29 1999-11-29
US09/450,857 1999-11-29
US45385099A 1999-12-02 1999-12-02
US09/453,850 1999-12-02
US49344400A 2000-01-28 2000-01-28
US09/493,444 2000-01-28

Publications (3)

Publication Number Publication Date
WO2000055633A2 WO2000055633A2 (fr) 2000-09-21
WO2000055633A3 true WO2000055633A3 (fr) 2001-02-22
WO2000055633A9 WO2000055633A9 (fr) 2001-11-22

Family

ID=27559474

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/007044 WO2000055633A2 (fr) 1999-03-15 2000-03-15 Methodes permettant de diagnostiquer du cancer colo-rectal, compositions, et methodes permettant de detecter des modulateurs du cancer colo-rectal

Country Status (6)

Country Link
EP (1) EP1163524A2 (fr)
JP (1) JP2004510951A (fr)
AU (1) AU3755300A (fr)
CA (1) CA2369319A1 (fr)
MX (1) MXPA01009369A (fr)
WO (1) WO2000055633A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981220A (en) 1996-03-27 1999-11-09 Human Genome Sciences, Inc. Epidermal differentiation factor
AU5918598A (en) 1997-01-16 1998-08-07 Human Genome Sciences, Inc. Human extracellular matrix-1
DE69939874D1 (de) 1998-09-02 2008-12-18 Diadexus Inc Verfahren zur diagnose, bewertung sowie bilddarstellung verschiedener krebserkrankungen
CA2401887A1 (fr) * 2000-03-16 2001-09-27 K.U. Leuven Research & Development Nusap, nouveau gene codant une proteine nucleaire de specificite tissulaire utile en tant qu'outil de diagnostic et agent therapeutique
US20030077568A1 (en) * 2000-09-15 2003-04-24 Gish Kurt C. Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators
MXPA03011985A (es) * 2001-06-20 2004-03-26 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores.
US20050272120A1 (en) 2001-06-20 2005-12-08 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7622260B2 (en) 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
AU2002324881A1 (en) * 2001-09-05 2003-03-18 Wesleyan University Diagnostic and prognostic tests
US7429450B2 (en) * 2001-11-15 2008-09-30 The Regents Of The University Of Michigan HIP1 cancer markers
US7473526B2 (en) 2002-03-29 2009-01-06 Veridex, Llc Breast cancer prognostic portfolio
US7348142B2 (en) 2002-03-29 2008-03-25 Veridex, Lcc Cancer diagnostic panel
US20060088537A1 (en) * 2002-04-11 2006-04-27 Terrett Jonathan A Protein involved in cancer
US7252976B2 (en) * 2002-08-28 2007-08-07 Board Of Regents The University Of Texas System Quantitative RT-PCR to AC133 to diagnose cancer and monitor angiogenic activity in a cell sample
EP1603514A4 (fr) * 2003-01-24 2007-08-22 Bayer Pharmaceuticals Corp Profils d'expression destines au cancer du colon et procedes d'utilisation
EP1895302A3 (fr) 2003-04-08 2008-05-14 Colotech A/S Procédé de détection d'un cancer colorectal dans des prélèvements humains
EP2311468B1 (fr) 2003-08-08 2014-01-15 Perseus Proteomics Inc. Gène surexprimé dans le cancer
NZ544432A (en) * 2005-12-23 2009-07-31 Pacific Edge Biotechnology Ltd Prognosis prediction for colorectal cancer using a prognositc signature comprising markers ME2 and FAS
US8450057B2 (en) 2006-08-14 2013-05-28 The Brigham And Women's Hospital, Inc. Diagnostic tests using gene expression ratios

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015602A1 (fr) * 1991-02-28 1992-09-17 Dana-Farber Cancer Institute, Inc. Diagnostic et therapie du cancer
WO1997041224A1 (fr) * 1996-04-26 1997-11-06 Amcell Corporation Antigene de cellules hematopoietiques humaines souches et parentes et leurs procedes d'utilisation
WO1997042209A1 (fr) * 1996-05-03 1997-11-13 Human Genome Sciences, Inc. Polypeptides humains de type rad
WO1999004030A1 (fr) * 1997-07-18 1999-01-28 The Johns Hopkins University Essais de criblage d'agents chimiopreventifs du cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015602A1 (fr) * 1991-02-28 1992-09-17 Dana-Farber Cancer Institute, Inc. Diagnostic et therapie du cancer
WO1997041224A1 (fr) * 1996-04-26 1997-11-06 Amcell Corporation Antigene de cellules hematopoietiques humaines souches et parentes et leurs procedes d'utilisation
WO1997042209A1 (fr) * 1996-05-03 1997-11-13 Human Genome Sciences, Inc. Polypeptides humains de type rad
WO1999004030A1 (fr) * 1997-07-18 1999-01-28 The Johns Hopkins University Essais de criblage d'agents chimiopreventifs du cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HÖRNER, S. ET AL.: "AC133-positive cells in the peripheral blood and bone marrow of patients with chronic myelogenous leukemia", BLOOD, vol. 92, no. 10, 15 November 1998 (1998-11-15), pages 316b, XP000937697 *

Also Published As

Publication number Publication date
JP2004510951A (ja) 2004-04-08
WO2000055633A2 (fr) 2000-09-21
AU3755300A (en) 2000-10-04
MXPA01009369A (es) 2003-06-06
WO2000055633A9 (fr) 2001-11-22
EP1163524A2 (fr) 2001-12-19
CA2369319A1 (fr) 2000-09-21

Similar Documents

Publication Publication Date Title
WO2001031335A3 (fr) Procede de criblage des modulateurs de proliferation cellulaire et procedes de diagnostic d'etats de proliferation cellulaire
WO2000055633A3 (fr) Methodes permettant de diagnostiquer du cancer colo-rectal, compositions, et methodes permettant de detecter des modulateurs du cancer colo-rectal
WO2002021996A3 (fr) Procede de diagnostic du cancer colono-rectal et compositions et procedes de criblage de modulateurs du cancer colono-rectal
WO2000055629A3 (fr) Nouvelles techniques permettant de traiter et de diagnostiquer le cancer du sein, compositions et techniques de criblage pour modulateurs de cancer du sein
WO2001011086A3 (fr) Nouvelles techniques de diagnostic de l'angiogenese, compositions et techniques de criblage pour modulateurs d'angiogenese
WO2002014503A3 (fr) Compositions et methodes de traitement et de diagnostic de cancers associes a her-2/neu
WO2002055988A3 (fr) Nouvelles techniques de diagnostic du cancer du sein, compositions et techniques de recherche de modulateurs du cancer du sein
WO2003025138A3 (fr) Procedes de diagnostic du cancer, compositions et procedes de criblage de modulateurs du cancer
WO2002099054A3 (fr) Hccs comme modificateurs de la voie p53 et methodes d'utilisation associees
WO2002016413A3 (fr) Vaccins
HK1022301A1 (en) Conjugates of cisdocosahexaenoic acid and paclitaxel
WO2002074156A8 (fr) Compositions et procedes de therapie et de diagnostic du cancer du colon
EP2062919A3 (fr) Compositions pharmaceutiques et procédés utiles pour moduler l'angiogénèse, inhiber la métastase et les fibroses de tumeur, et évaluer les tumeurs malignes parmi les tumeurs du cancer du colon
AU9312198A (en) Genes amplified in tumours, antibodies against the proteins encoded thereby, andtheir use in diagnosis and treatment of cancer
WO2002012328A8 (fr) Compositions et methodes utilisees dans la therapie et le diagnostic du cancer du colon
WO2002058534A3 (fr) Compositions et methodes pour le traitement et le diagnostic du cancer du colon
WO2002016939A3 (fr) Procedes de diagnostic du cancer, compositions et procedes de depistage de modulateurs du cancer
WO2002012280A3 (fr) Compositions et procedes pour le diagnostic et le traitement du cancer du colon
WO2002039885A3 (fr) Compositions et methodes destinees a la therapie et au diagnostic du cancer de l'ovaire
WO2002059609A3 (fr) Procede de diagnostic du cancer du sein et/ou du cancer colorectal, compositions, et procedes de criblage de modulateurs du cancer du sein et/ou du cancer colorectal
WO2001090152A3 (fr) Compositions et procedes pour la therapie et le diagnostic du cancer du sein
WO2002021134A3 (fr) Nouveaux procedes permettant de diagnostiquer le cancer du sein, compositions et procedes de criblage pour modulateurs de cancer du sein
WO2004041076A3 (fr) Methodes de detection du cancer colorectal
WO2004075839A3 (fr) Methodes et compositions pour moduler l'apoptose
WO2000040752A3 (fr) Genes associes a des cancers et leurs produits

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 605214

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/009369

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2000916451

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2369319

Country of ref document: CA

Ref country code: CA

Ref document number: 2369319

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/236-236/236, DRAWINGS, REPLACED BY NEW PAGES 1/454-454/454; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWP Wipo information: published in national office

Ref document number: 2000916451

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000916451

Country of ref document: EP